1492 Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

1492 Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.78M	Buy	+118,156	New	+$3.02M	1.06%	38
2023 Q3	–	Sell	-222,767	Closed	-$2.12M	–	94
2023 Q2	$2.12M	Sell	222,767 -749	-0.3%	-$8.31K	1.24%	32
2023 Q1	$2.46M	Buy	223,516 +48,970	+28%	+$708K	1.52%	22
2022 Q4	$2.58M	Sell	174,546 -3,774	-2%	-$65.9K	1.67%	20
2022 Q3	$3.41M	Buy	178,320 +361	+0.2%	+$8.18K	2.45%	10
2022 Q2	$3.79M	Buy	177,959 +102,767	+137%	+$2.11M	2.49%	5
2022 Q1	$1.45M	Buy	+75,192	New	+$1.27M	0.77%	47

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1492 Capital Management's ARQT Position: Q1 2026 in Review

1492 Capital Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q1 2026: 118,156 shares worth $2.78M. The stake represents 1.06% of the portfolio and ranks #38 among its holdings. This is a return to the name: 1492 Capital Management previously reported a position in ARQT as recently as Q2 2023.

1492 Capital Management first reported a position in ARQT in Q1 2022 and has held it in 7 quarters since. The position peaked at $3.79M in Q2 2022. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

1492 Capital Management held 118,156 shares of Arcutis Biotherapeutics worth $2.78M as of Q1 2026.
Arcutis Biotherapeutics was a new 1492 Capital Management position in Q1 2026.
Arcutis Biotherapeutics made up 1.06% of 1492 Capital Management's portfolio in Q1 2026, its #38 holding.
1492 Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 7 quarters since.
1492 Capital Management's Arcutis Biotherapeutics position peaked at $3.79M in Q2 2022.
269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.